Access to medicines report discussed by Rose-Marie Boylan

https://accesstomedicinefoundation.org/sectors-and-research/index-ranking

This report highlights the companies that have excelled in providing patient access. Negotiating global agreements for drugs and planning the sequence of drug launches in various markets requires significant compromise and collaboration.

Crucially, the strategist undertaking this task must possess a pragmatic business mindset combined with a generous and globally aware philanthropic outlook. This means the combination of hard-headed business sense, strategic foresight with a balanced philanthropic perspective on healthcare policy.

Many in the business world are driven by greed; this narrow viewpoint is ineffective in matters of market access and pharmaceutical pricing within government and public affairs. This approach is detrimental to the goals of government and public affairs in the pharmaceutical sector. Especially when aiming to provide global access to high-priced, life-changing, or life-saving medications.

The strategy and its operational execution can fail if a company, lacking understanding and systems thinking, overlooks this. To create an effective global strategy, it is crucial to avoid being blindsided by greed or short-term thinking. All markets, international pricing strategies must be sequenced using this strategic thinking and world view on patient access.

https://accesstomedicinefoundation.org/sectors-and-research/index-ranking